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The progressive muscular damage in patients affected by 
Glycogenosis  type  II  can  be  slowed  down  through  lifestyle 
changes based on a specific dietotherapy and daily physical ex-
ercise. Dietary treatment provides for a diet made up of pro-
teins (25-30%), carbohydrates (30-35%), fat (35-40%), that is a 
high-protein diet for the most part. Patients suffering such the-
saurismosis need a higher amount of proteins since the increase 
in amino acids, which function as substrate for the synthesis of 
proteins, could make up for the proteolysis of muscular tissue. 
Proteins coming from meat, fish, egg, and dairy products are to 
be preferred; such food, moreover, is rich in alanine, an amino 
acid playing a key role in glycide metabolism and, consequently, 
in the employment of glucose as a source of energy. So much 
so that a further oral supplement is recommended, in a dose of 
0,4g/kg divided 3-4 times per day. Lipids are recommended in 
the form of unsaturated fats (omega-3, which are mainly con-
tained in bluefish) and saturated fats (omega-6, which are main-
ly contained in olive oil, dried fruit and cereals), reducing to 
a minimum saturated ones due to their aterogenic effect. The 
assumption of carbohydrates must not only be reduced to 30-
35%, but also distributed in the space of a day. The “a little and 
often” rational consists in avoiding the build-up of glycogen on 
the one hand, and hypoglycaemia on the other. Among complex 
carbohydrates wholemeal ones such as cereals, legumes, and 
wholemeal pasta are to be preferred, in small helpings; whereas, 
among simple ones, dried or skinned (if fresh) fruit; such recom-
mendation aims at increasing the input of fibres in order to coun-
ter constipation, which is often found in those patients. Muscular 
pain, in fact, can also concern the gastrointestinal system, with 
consequent  dysphagia,  gastroesophageal  reflux,  gastroparesis 
and a reduction in appetite. Such conditions are treated with die-
tary and pharmacological measures to avoid malnutrition. In the 
team in charge of treatment, the presence of a physiotherapist is 
essential to carry out exercises in coordination and contraction 
of facial muscles, postural training and rehabilitation to tasting. 
Anthropometric data and bodily composition represent param-
Testing); c. pain with several scales such as VAS (Visual Ana-
logic Scale), Pediatric Pain Objective scale, and BPI (Brief Pain 
Inventory) (3) global functioning with the Six Minute Walk (4) 
and the Gross Motor Function Measure (GMFM) (5) disability 
with the Pediatric Evaluation of Disability Index (PEDI), (6) the 
Pompe PEDI,(7) the Functional Independent Measure (FIM), 
(8) the WeeFIM, (9) the Barthel Index (10) and the ADL (11)/
IADL(12); quality of life with the Rotterdam Handicap Scale 
(RHS) (13) and the Short Form 12 (SF-12)(14). In particular, 
in patients with Pompe disease we have to deal with a deep, 
progressive and symmetrical muscle weakness, proximal more 
than distal, involving the lower extremities more frequently than 
the upper ones, that will determine contractures and deformi-
ties. Moreover there are often neck and trunk muscle weakness 
involving respiratory muscles (diaphragm, intercostals, abdomi-
nal and accessory muscles) and this might lead to respiratory 
failure. Facial and oralmotor weakness is responsible not only 
of problems of mastication and phonation, but can also give the 
typical myopathic facies. In terms of functional limitations, my-
opathic patients experience deficit of walking ability resulting in 
the need of orthoses or wheelchair, loss of personal autonomy in 
the activities of daily living, relational-communicative, mental 
and emotional disabilities. The rehabilitation management of 
Pompe disease should be comprehensive and preventive, based 
on an understanding of the pathogenesis of disease progression 
and on individual assessment. The key of management lies in 
considering the interaction between the presence, progression 
and potential remediation of weakness and fatigue. It should op-
timize and preserve motor and physiological function, prevent 
or minimize secondary complications, promote and maintain the 
maximum level of functional independence and participation, 
and improve the quality of life; maximize the benefits of therapy 
recombinant and other therapies when they become available.
The  rehabilitative  approach  is  nowadays  mandatory  for 
comprehensive management of patients affected by metabolic 
myopathies.
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disease confirmed by a biochemical and molecular genetic ex-
aminations (1).
So far, ERT has been generally prescribed to patients with 
motor symptoms (muscle weakness) and/or respiratory involve-
ment.
Exclusion criteria encompassed a severe associated illness 
which would be expected to greatly shorten life expectancy. 
Alglucosidase (Myozyme) is administered biweekly i.v. as 
20 mg/kg. Although the high costs of the drug, in several Euro-
pean countries the patients are fully supported by their Minis-
tries of Health. 
In fact, in Belgium, National guidelines consider every pa-
tient with clinical symptoms of muscle and/or respiratory in-
volvement as a candidate for ERT that, on the other hand, should 
not be started in patients showing neither a clinical impact of the 
disease or with a limited life expectancy.
In the Netherlands, the inclusion criteria are the confirma-
tion of diagnosis via enzyme assay and mutation analysis, and 
patients should have demonstrable muscle weakness and/or pul-
monary function < 80%.
In UK, specific guidelines, prepared by a multidisciplinary 
group (2007), included patients with muscle weakness and/or 
respiratory compromise leading to an impaired quality of life as 
candidate for treatment. 
In  France,  Pompe  disease  experts  recommend  to  treat 
symptomatic patients (muscle weakness and/or respiratory in-
volvement - FVC < 80%). 
In Germany and in Poland there is a generic recommenda-
tion to treat symptomatic patients. 
In addition, in Brazil there is a recommendation to treat 
symptomatic patients; mild cases have to be progressively fol-
lowed by respiratory and /or muscular functional tests and/or by 
muscle MRI before starting ERT. 
Because  of  the  high  costs  of  ERT,  in  several  countries 
Health authorities (and EMA in Europe) request precise data 
concerning the clinical effects and safety of ERT to reimburse 
the treatment.
Given the data obtained in different cohorts of patients, 
treated with ERT, there is a clear evidence that alglucosidase 
improves  the  walking  distance  and  stabilizes  the  pulmonary 
function. A precise monitoring should help to make a decision 
for initiating or even interrupt ERT
Patients should be followed in specialized neuromuscular or 
metabolic Departments, in connection with a pulmonology unit.
Follow-up visits should be organized every 6 months or 
once a year with clinical evaluations performed by expert physi-
cians and trained physiotherapists; those results should be col-
lected on dedicated data base/registries.
To date, there is a need of specific outcome measures to 
monitor patients before treatment and during the follow up.
Across various European countries and US, clinical assess-
ment has been differentially monitored. In fact 6 MWT, MMT, 
MFM scale, timed tests (i.e. GSGC), WGMS, muscle MRI, SF-
36, have been applied every 3-6 months/1 year to patients. 
Since  2006,  AIFA  (Agenzia  Italiana  del  Farmaco)  has 
approved alglucosidase alfa (Myozyme) for the treatment of 
Pompe disease patients in Italy, either for infantile or late-onset 
patients. 
eters that must be carefully considered to monitor the clinical 
picture and the response to treatment. Calculation of the body 
mass index (BMI), plicometry and waistline measurement are 
useful evaluations, but they are not enough for the study of fat 
and muscle mass. To this end, bodily bioimpedentiometry (BIA) 
is a system of enquiry more frequently used. Pompe disease is 
a cronic, progressive, and crippling disease, so an appropriate 
lifestyle is necessary, which can be obtained by learning how to 
self-manage the disease. Dietary advice is not enough: a biopsy-
chopedagogic  approach,  based  on  an  empathetic  relationship 
between patient and medical team, is necessary.
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Pompe disease is a rare lysosomal disorder of muscle gly-
cogen metabolism due to alfa-glucosidase (GAA) deficiency. 
The prevalence of this disease is estimated to be 1:40.000. 
Since 2006, Enzyme Replacement Therapy (ERT) became 
available in Europe and US. So far, there are no officially ap-
proved  international  guidelines  about  ERT  inclusion  criteria 
of patients but they must have a defined diagnosis of Pompe 